A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma

NCT06006286 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped 0 participants registered

Conditions

Metastatic Hepatocellular Carcinoma

Interventions

DRUG: Atezolizumab
DRUG: Bevacizumab
DRUG: ADI-PEG 20

Sponsor

M.D. Anderson Cancer Center